Benedetta di Robilant

No cap, here’s what’s up with Benedetta di Robilant – this woman is the real deal. She’s a scientist turned startup founder, and she’s been crushing it in biotech and longevity since forever.

So, she’s got a serious background, degrees in Medical Biotechnology, then a PhD in Molecular Medicine from San Raffaele University. The girl’s been deep in the labs, working on immune systems, stem cells, all that modern stuff. She’s done stints at big names like Genentech and Stanford, where she met her co-founder. That’s where they started bouncing ideas and dreaming big about fixing aging at the cellular level.

Fast forward, she co-founded Dorian Therapeutics in 2018, right into YC’s Summer batch. That’s no small feat, Y Combinator is the real deal, and getting in means she’s got serious hustle. Dorian’s all about developing “senoblockers”, basically, new drugs to fight age-related diseases and make tissues healthier again. They’re in the longevity game, trying to crack how to slow down aging or even reverse some of it.

What’s cool is she’s more than just a scientist. She’s been recognized at big industry events like the JP Morgan Healthcare Conference, so investors and biotech giants are paying attention. Plus, she’s in StartX’s S19 cohort, plugged into that startup scene, always pushing the limit between research and real-world impact.

Her process? It’s all about pushing the limits of what’s possible. From Stanford research to Genentech, then jumping into startup world with Dorian, she’s been chasing the big questions: how do we live longer, healthier lives? And she’s doing it by building the tools, the biotech innovations that could change everything.

Bottom line? Benedetta’s not just a scientist. She’s a visionary, a builder, someone who jumped from academia into the startup world and is now leading a biotech revolution. No bullshit, she’s the kind of person who sees the future and says, “Yeah, I’m gonna make that happen.” And she’s doing it.